Home › Rectal Fistula › NCT05243966
Myriad™ Augmented Soft Tissue Reconstruction Registry
RecruitingObservational study
Registry of Myriad™ Utilization in Soft Tissue Reconstruction Procedures
Who can join
Ages 18 and older · All sexes
Full eligibility criteria
Inclusion Criteria:
* Willing and able to provide written informed consent and to comply with the requirements of Clinical Investigational Plan
* Male or female patients aged 18 years or above
* Patients where Matrix and/or Morcells were used as part of their soft tissue reconstruction procedure
* Subject that are willing and able to comply with all aspects of the treatment and evaluation schedule
Exclusion Criteria:
* Patients with known sensitivity to ovine (sheep) derived material
* Patients with full thickness ('third degree') burns
* Patients with wounds with uncontrolled clinical infection (CDC Contamination Grade=4)
* Any medical condition or serious intercurrent illness that, in the opinion of the investigator, may make it undesirable for the patient to participate in the study
* Patient is currently participating or has participated in another clinical study within past 30 days prior to enrollment
* Pregnant or lactating women
* Any subject who, at the discretion of the Investigator, is not suitable for inclusion in the studyAbout the study
This is an observational study designed to evaluate the safety and clinical outcomes of Myriad™ in soft tissue reconstruction procedures. The study will enroll participants who are undergoing a surgical procedure, where the attending physician will use Myriad™ as part of the surgical intervention.
What is being tested
- Myriad Matrix™ and Myriad Morcells™ (device)
Sponsor: Aroa Biosurgery Limited · Participants: 800 · Started: Jan 10, 2022
Contact the study team
- Barnaby May, PhD · Phone: +64 21 056 9995
Official record on ClinicalTrials.gov — NCT05243966
Locations in the U.S.
Conditions
From ClinicalTrials.gov, data retrieved Sep 30, 2026. Each study sets its own eligibility; the study team decides who can join.